The idea of polypharmacology describes the ability of a molecule to interact with two or more targets at once. When compared to traditional single-targeting compounds, it has numerous advantages. Several proteins and pathways are involved in the initiation and progression of complex and multifactorial diseases such as cancer. A chemical must be promiscuous, or able to interact with various targets, to be considered polypharmacologic. It must also be able to avoid attaching to anti-targets, which would cause off-target negative effect. Researchers anticipate whether or not a developed molecule will be promiscuous by looking for specific structural traits and physicochemical qualities. Promiscuity is determined using cutting-edge, modern computational techniques. The "one drug, multiple targets" polypharmacology paradigm has many uses, particularly in drug repurposing which is the process of developing an already-approved medication for novel use. Details on how one might purposefully introduce promiscuity into compounds to make them polypharmacologic are also provided in this review.
No takes yet. Share an insight, caveat, or question.
Waad A. Samman (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: